

NUCLEOTIDE SEQUENCES ENCODING VARIABLE REGIONS OF
HEAVY AND LIGHT CHAINS OF MONOCLONAL ANTIBODY 1F7, AN
ANTI-IDIOTYPIC ANTIBODY REACTIVE WITH ANTI-HIV ANTIBODIES

Field of the Invention

The present invention relates to nucleotide sequences that encode the complementarity-determining regions (CDRs) and framework regions (FR) of antibodies. The invention particularly relates to CDRs and FRs of anti-idiotypic antibodies that recognize the idiotopes of anti-HIV antibodies. The nucleotide sequences are pertinent to modulation of the immune response to HIV in HIV-1 infected individuals, as by therapeutic vaccination with the anti-idiotypic antibodies or antibody fragments they encode, as well as by direct therapeutic administration as DNA molecules.

Background of the Invention

Acquired Immune Deficiency Syndrome (AIDS) has claimed the lives of millions of people worldwide and continues to be a leading cause of death, particularly in under-developed countries. The primary etiologic agent of AIDS is widely accepted to be one or more strains of the human immunodeficiency virus (HIV). The most studied strain of HIV is the type 1 strain (HIV-1), which is also referred to as HTLV-III. An intact HIV-1 virion is roughly spherical and presents an outer glycoprotein membrane covered with distinctive knobs and spikes.

Following initial infection with HIV is an asymptomatic stage during which the host harbors the virus and tests seropositive for HIV-1 antibodies. This stage can last as long as five years or more. This stage is followed by an AIDS-related complex stage (ARC) and, finally, AIDS. The final stage of AIDS is characterized by a variety of opportunistic infections due to the reduced vitality of the immune system. Although several drugs and drug combinations have been shown to alleviate the symptoms of AIDS and evidently reduce the viral load, to date, no effective prophylactic or therapeutic vaccine against HIV infection has been approved.

One approach proposed for the development of novel therapeutic antibodies or therapeutic vaccines, as well as prophylactic co-vaccines, employs so-called anti-

idiotypic antibodies, and fragments thereof. A second strategy for modulation of immune response against viral infection involves direct inoculation of tissues *in vivo* with DNA encoding the VH and/or VL chains of an anti-idiotypic antibody as a therapeutic DNA vaccine.

5 Previously, an anti-idiotypic antibody has been shown to induce immune modulation in HIV infection. A murine anti-idiotypic antibody (designated 1F7 and produced by hybridoma ATCC Accession No. HB 11286) has been raised against pooled human anti-HIV-1 antibodies. [Mueller, S., *et al.*, *J. Immunol.* (1991), 147:933-941]. The 1F7 idiotype is shared by human anti-HIV-1 antibodies having specificity for different
10 proteins (envelope, core, and reverse transcriptase) of HIV-1, and the idiotype is shared by more than 70% of HIV-infected individuals. [Wang, H. *et al.*, *Eur. J. Immunol.* (1992), 22:1749-1755]. The 1F7 idiotype occurs in high levels among patients with HIV lymphoma; however, this is shown to be due to HIV infection rather than B-cell neoplasia or abnormal B-cell proliferation. [Herndier, B., *et al.*, *Hybridoma* (1993), 12:
15 529-537]. Findings suggest that the 1F7 idiotype is a marker for B-cell clones induced during the primary immune response to HIV and maintained throughout life. [Mueller, S., *et al.*, *Hybridoma* (1997), 16: 17-21].

The potential for Mab 1F7 as a therapeutic antibody (therapeutic vaccine) has recently been demonstrated in rhesus macaques infected with a simian variant of HIV
20 (SHIV-IIIB). [S. Mueller, *et al.*, *PNAS* (1998) 95: 276-281; U.S. Patent No. 6,057,421]. In these studies, a series of intravenous injections of purified 1F7 antibody enhanced and broadened the macaques' virus neutralizing antibody response to the simian virus. This result suggests the potential of beneficially modulating the immune response of chronically HIV-1 infected individuals without clinical side effects in addition to, or
25 during breaks in, antiviral drug therapy.

The functionality of the anti-idiotypic antibody 1F7 may be exploited directly according to the following approaches:

- (1) 1F7 can be applied as a post-exposure therapy to modulate the locked-in
immune response and thereby facilitate an effective immune response to virus
30 variants. Thus, a deceptive, locked-in immune response to HIV antigens is modified by applying 1F7 as therapeutic vaccine in chronically HIV-infected

individuals and AIDS patients in order to achieve an immune response able to overcome virus variants that had escaped the previous, locked-in immune response set by HIV infection. (Kohler, H., *et al.*, *Immunology Today* (1994)). Deceptive imprinting has been described in a review as an immune reaction in HIV and parasitic infections, i.e., it is based on “Original Antigenic Sin” (OAS) of an immune response. [Veljkovic, V., *et al.*, *Vaccine* (2001), in press]. OAS is defined for infectious pathogenic organisms such as influenza, dengue, malaria, and HIV, as imprinting or B cell dominance of the host’s immune response by the antigenic make-up of the virus or parasite at first encountered during infection. The imprinting leads to an insufficient or “deceptive” immune response due to B cell dominance that prevents an adequate immune response to the challenge by a rapidly mutating virus or parasite within the host.

(2) 1F7 can be used as a prophylactic co-vaccine when applying gp120-based and other HIV protein-based prophylactic subunit vaccines in HIV seronegative individuals at risk of HIV infection. In this approach, deceptive imprinting by HIV potentially induced by subunit vaccines as recombinant gp120 (Veljkovic, *et al.*, 2001) can be counteracted by co-administration of 1F7.

(3) 1F7 can be used during “structured therapy interruption” (STI) in HIV-infected patients treated early on with antiviral drugs. [Rosenberg, E., *Nature* (2000) 407: 523]. STI has been reported to restore a short-term immune response on T cell levels being able to fight virus variants. Co-application of the 1F7 antibody can be helpful to prolong a diversified immune response to HIV induced by STI.

In view of the demonstrated therapeutic potential of Mab 1F7 in a suitable primate model, the immunoreactive fragments of 1F7 can also be employed for therapeutic benefit. Thus, recombinant DNA techniques can be employed to isolate and manipulate the nucleotide sequences encoding the variable heavy (VH) and variable light (VL) regions of the 1F7 antibody. For instance, the variable chains of the murine antibody can be fused to the constant gamma or kappa/lambda regions of human immunoglobulins (Igs) to afford human/murine chimeras, which display the

complementarity-determining regions (CDRs) and/or framework-determining regions (FRs) of 1F7. Such human/murine chimeric antibodies are expected to reduce the human anti-murine antibody (HAMA) response often encountered in passive immunization therapy, thereby affording better-tolerated vaccines. In general, such chimeric antibodies

5 show an increase in biological half-life *in vivo*. They also are capable of efficiently mediating the antibody-dependent complement cascade (ADCC), antibody-dependent macrophage cytotoxicity (ADMC), and complement fixation.

Chimeric antibodies often, however, remain immunogenic in primates due to the presence of murine variable regions. Another approach to reducing the immunogenicity

10 of murine variable regions is to mutate the VH and VL chains of the 1F7 antibody to homologous human sequences, while retaining the murine CDRs and/or FRs, i.e., the variable chains are "humanized" [Mateo, C, *et al.*, *Immunotech.*, (1997), 3: 71-81]. Linking the modified murine variable regions to human constant regions can afford chimeric antibodies in which the HAMA response is nullified.

15 The development of humanized murine antibodies has afforded exciting new therapeutics in recent years for a variety of illnesses, notably, non-Hodgkin's lymphoma, breast cancer, among others. Antibody products now account for the single largest group of biotechnology-derived molecules in clinical trials; to date, however, no antibody product has been approved for the treatment of HIV infection.

Summary of the Invention

The present invention is directed to one or more isolated polynucleotides containing at least one nucleotide sequence encoding a complementarity-determining region (CDR) and/or a framework-determining region (FR) of an anti-idiotypic antibody

25 that binds to the idiotopes of anti-HIV-1 antibodies. The aforementioned anti-idiotypic antibody is preferably Mab 1F7 produced by the hybridoma having American Type Culture Collection (ATCC) Accession No. HB 11286. Depending upon the precise nature of the polynucleotide, a single CDR, a single FR, combinations of these, or an entire variable heavy (VH) or variable light (VL) chain of the anti-idiotypic antibody can be

30 encoded. Moreover, murine regions outside the CDRs can be mutated or replaced with human immunoglobulin sequences in order to humanize the antibody or fragment thereof.

Typically, a DNA molecule of the invention is used to obtain a polypeptide containing more than one CDR and/or FR of the 1F7 antibody. For instance, the DNA molecule can be used to transform a suitable non-human host to express a VH and/or VL chain peptide of 1F7. The VH and VL chain peptide can be fused to the corresponding constant heavy and light chain peptides for mice or humans by covalently linking the DNA molecules to the appropriate segments of the immunoglobulin genes. Whenever the complete heavy and light chains are co-expressed, an assembled murine 1F7 or human/murine chimeric analog of 1F7 is provided, which can be used in a passive immunization protocol. Alternatively, a DNA molecule encoding the at least one CDR and/or FR of the 1F7 antibody can be used directly as a DNA vaccine, e.g., by injection of muscle cells with “naked DNA”. The afforded antibody product is thus: (i) a “humanized” antibody; (ii) a CDR/FR grafted antibody; or (iii) a “de-immunized” antibody with removed or altered murine antigenic residues. The therapeutic effect of such an antibody is a broadening and increase of virus neutralization.

A particularly preferred aspect of the invention employs murine nucleotide sequences encoding the CDRs of the VH and VL chains of Mab 1F7, which have the amino acid sequences shown in SEQ ID NOS: 11, 15, 19, 28, 32 and 36. Also preferred are those murine nucleotide sequences encoding the FRs of the VH and VL chains of 1F7 having the amino acid sequences shown in SEQ ID NOS: 9, 13, 17, 21, 26, 30, 34 and 38. It is to be appreciated that the present invention contemplates and includes all nucleotide sequences equivalently encoding the aforementioned murine amino acid sequences by virtue of the degeneracy of the genetic code.

Detailed Description of the Invention

The present invention is directed primarily to a polynucleotide that contains one or more nucleotide sequence encoding a complementarity-determining region (CDR) and/or a framework-determining region (FR) of an anti-idiotypic antibody. Centrally of interest are anti-idiotypic antibodies that recognize (bind to) anti-HIV-1 antibodies, e.g., in sera. Particularly of interest are the CDRs and FRs of the murine monoclonal antibody 1F7 [Mueller, S., *et al.*, *J. Immunol.* (1991), 147:933-941].

The CDRs and FRs referred to for the present invention are those occurring in the variable heavy (VH) and variable light (VL) chains of the anti-idiotypic antibody.

Typically, three CDRs and four FRs occur in the full variable chains, both heavy and light. However, it should be appreciated that the present invention is not limited to those polynucleotides encoding a complete variable chain, or even all of the CDRs or FRs of a variable chain. For instance, since a single CDR has some affinity for anti-HIV antibodies, it is of interest as a probe for the presence of these antibodies and can have a modulating effect in therapeutic regimens either alone or as part of a larger molecule.

In a preferred aspect of the invention, a polynucleotide comprises a nucleotide sequence that encodes at least one VH or VL chain CDR or FR of Mab 1F7. The amino acid sequences of the three VH CDRs, four VH FRs, three VL CDRs and four VL FRs of 1F7 are shown in the Sequence Listing according to the following assignments:

Variable heavy chain amino acid sequences

VH FR1: SEQ ID NO: 9
 VH CDR1: SEQ ID NO: 11
 VH FR2: SEQ ID NO: 13
 VH CDR2: SEQ ID NO: 15
 VH FR3: SEQ ID NO: 17
 VH CDR3: SEQ ID NO: 19
 VH FR4: SEQ ID NO: 21

Variable light chain amino acid sequences

VL FR1: SEQ ID NO: 26
 VL CDR1: SEQ ID NO: 28
 VL FR2: SEQ ID NO: 30
 VL CDR2: SEQ ID NO: 32
 VL FR3: SEQ ID NO: 34
 VL CDR3: SEQ ID NO: 36
 VL FR4: SEQ ID NO: 38

Generally, it is desired that a polynucleotide of the invention includes a nucleotide sequence encoding all of the CDRs and FRs of a respective VH or VL chain of 1F7 in a single molecule. An amino acid sequence of a polypeptide so expressed is shown in SEQ ID NO: 7 for a VH chain and in SEQ ID NO: 24 of a VL chain. An immune modulator polypeptide thereby expressed contains murine CDR and FR sequences. Alternatively, the polypeptide can include the respective murine CDR amino acid sequences (SEQ ID NOS: 11, 15, and 19 for VH and SEQ ID NOS: 28, 32, and 36 for VL) with these being flanked by human or primate Ig amino acid sequences, i.e., replacing the murine FRs.

A foregoing CDR and/or FR can be encoded by a native 1F7 nucleotide sequence or by a degenerate sequence that encodes the same peptide. Therefore, exemplary, but not exclusive, nucleotide sequences are those shown in the Sequence Listing according to the following assignments:

Variable heavy chain nucleotide sequences

VH FR1: SEQ ID NO: 8
 VH CDR1: SEQ ID NO: 10
 VH FR2: SEQ ID NO: 12
 VH CDR2: SEQ ID NO: 14
 VH FR3: SEQ ID NO: 16
 VH CDR3: SEQ ID NO: 18
 VH FR4: SEQ ID NO: 20

Variable light chain nucleotide sequences

VL FR1: SEQ ID NO: 25
 VL CDR1: SEQ ID NO: 27
 VL FR2: SEQ ID NO: 29
 VL CDR2: SEQ ID NO: 31
 VL FR3: SEQ ID NO: 33
 VL CDR3: SEQ ID NO: 35
 VL FR4: SEQ ID NO: 37

Conventionally, a polynucleotide of the invention contains a nucleotide sequence encoding all of the CDRs and FRs of a respective VH or VL chain of 1F7 in a single molecule. Exemplary nucleotide sequences, which in this case are the native sequences of 1F7, are shown in SEQ ID NOS: 5 and 22 for the full-length VH and VL genes, respectively. Alternatively, the murine nucleotide sequences encoding the CDRs, e.g., SEQ ID NOS: 10, 14, and 18 for the VH segments and SEQ ID NOS: 27, 31, and 35 for the VL segments, can be flanked by human Ig nucleotide fragments to replace the corresponding murine FRs. The human Ig sequences, e.g., constant region sequences, are operably linked in frame with the murine Ig sequences to maintain the coding integrity of the molecule and ensure correct peptide expression.

A polynucleotide of the invention can be inserted into (and conveniently stored in) a suitable vector, such as an expression plasmid, to permit transfection and expression in a suitable host cell line. The selected CDR- and/or FR-encoding nucleotide sequence is operably linked to a promoter of the vector, which promoter effects expression under conditions inherent to, or induced in, the cell line. Subsequent secretion of the resultant protein affords one or more polypeptide displaying the selected CDRs and/or FRs. Cell lines commonly employed for the expression of such immunoglobulins include myelomas, Chinese hamster ovary (CHO) cells, or insect cells.

As suggested above, a polynucleotide of the invention encoding a CDR and/or FR of 1F7 can be operably linked to a corresponding nucleotide sequence encoding a human Ig constant region to encode chimeric antibodies. For instance, a nucleotide sequence encoding the murine full-length VH chain of 1F7 can be operably linked to a nucleotide sequence encoding a human VH constant region. Likewise, the full-length VL nucleotide sequence can be operably linked to a nucleotide sequence encoding a human VL constant region. Expression of the resultant polypeptides in a suitable host can afford assembled human/murine chimeric antibodies having the desired anti-idiotypic properties, increased lifetimes, and improved tolerance.

It is anticipated that, when used as immune modulators/therapeutic vaccines, certain polypeptides generated by the polynucleotides of the present invention may stimulate a human anti-mouse antibody (HAMA) immune response in a human host due to the presence of excessive murine sequences in the molecule, which can limit

therapeutic application. In such instances, it may be desired to “humanize” the sequences by incorporating appropriate human amino acid sequences in the peptide at positions flanking the murine CDRs (CDR-grafting).

Thus, in a further embodiment, a polynucleotide of the invention can be mutated using conventional recombinant DNA methods to provide homologous human Ig sequences within the VH and VL chains of 1F7 while retaining one or more of its murine CDRs and/or FRs. The CDRs of the expressed polypeptide, especially when acting in concerted fashion, can elicit or modulate an immune response to HIV infection, with the “humanized” FRs mitigating the HAMA effect, prolonging lifetimes, etc. Such humanized variable chains can additionally be linked as above to human constant regions to afford chimerics in which the murine sequences are localized to the CDRs.

Although the foregoing polynucleotides and associated polypeptides are anticipated to be particularly useful in therapeutic applications, it is anticipated that they can also be used in diagnostic applications, e.g., to detect HIV-1 infection, by virtue of their respective abilities to bind to anti-HIV antibodies in sera. Briefly, a polypeptide of the invention can be immobilized on a support and bound to a labeled ligand, e.g., an anti-HIV antibody. Loss of signal from the support in the presence of a serum sample would thereby indicate the presence of competing anti-HIV antibodies in the sample. Further protocols that can be employed, such as those employing primary and labeled secondary antibodies, as described by Self (U.S. Patent No. 4,769,321), the disclosure of which is incorporated herein by reference. Moreover, a polypeptide of the invention can be employed in the assay protocols described by Cosand (U.S. Patent No. 4,629,783) for synthetic peptide antigens in the detection of AIDS-related disease. Additionally, a polypeptide of the present invention can be linked to a larger non-immunogenic peptide as described by Cosand, the disclosure of which is incorporated herein by reference.

It should be appreciated that the nucleotide sequences described and claimed herein have functional equivalents by virtue of the degeneracy of the genetic code. Those equivalents are known to the skilled, or even novice, practitioner and are expressed in terms of equivalent codons for defining a given amino acid. Thus, it is contemplated that codons equivalent to those set forth in the Sequence Listing hereinafter can be substituted for those given in the Sequence Listing. Due to the vast number of equivalent nucleotide

sequences afforded by the genetic code, all of the possible sequences are not set forth herein. Instead, equivalent codons are hereby identified according to the degeneracy of the genetic code as shown in Table 1 (where the U base of mRNA corresponds to the T base of DNA, cf. Stryer, L., Biochemistry, 1988, W.H. Freeman & Co., NY, p. 107).

- 5 Thus, nucleotide sequences additional to those given in the Sequence Listing are readily identified and are contemplated within the present invention.

TABLE 1

Second Base

First Base	U	C	A	G	Third Base
U	Phe	Ser	Tyr	Cys	U
	Phe	Ser	Tyr	Cys	C
	Leu	Ser	Stop	Stop	A
	Leu	Ser	Stop	Trp	G
C	Leu	Pro	His	Arg	U
	Leu	Pro	His	Arg	C
	Leu	Pro	Gln	Arg	A
	Leu	Pro	Gln	Arg	G
A	Ile	Thr	Asn	Ser	U
	Ile	Thr	Asn	Ser	C
	Ile	Thr	Lys	Arg	A
	Met	Thr	Lys	Arg	G
G	Val	Ala	Asp	Gly	U
	Val	Ala	Asp	Gly	C
	Val	Ala	Glu	Gly	A
	Val	Ala	Glu	Gly	G

- 10 As mentioned above, it is anticipated that one aspect of the invention entails replacing those regions outside the aforementioned CDRs of the variable heavy and light chains of 1F7 with amino acid sequences from another species, e.g., human. Stated alternatively, this can involve replacing the CDRs of human antibodies with the CDRs of 1F7. This aspect of the invention is typically performed by altering a human genetic

template by site-directed mutagenesis to afford the desired murine CDRs of Mab 1F7. One such method of making altered antibodies employs recombinant DNA techniques as described in U.S. Patent No. 5,225,539, the disclosure of which is incorporated herein by reference. A further method of making humanized antibodies having one or more CDRs and possible additional amino acids, e.g., in a framework region, from a donor immunoglobulin is described in U.S. Patent No. 5,530,101, the disclosure of which is incorporated herein by reference. A good review of recombinant CDR grafting techniques, including protocols, for providing humanized antibodies having murine CDRs is described in Antibody Engineering, 2nd ed., C. Borrebaeck, ed., Chpt. 6, pp. 159-183, the disclosure of which is incorporated herein by reference. The latter reference also describes protocols for expression of humanized variable chain genes, e.g., in mammalian cells, as well as detection and purification techniques.

A further aspect of the invention concerns incorporation of an aforementioned polypeptide of the invention within a pharmaceutical composition that further contains a pharmaceutically acceptable carrier. Such carriers are well known within the art and are set forth, for example, in U.S. Patent No. 6,057,421, which disclosure is incorporated herein by reference.

As suggested hereinabove, a polynucleotide or polypeptide of the invention can be employed to modulate the immune response of a host infected with HIV. This implementation is illustrated in U.S. Patent No. 6,057,421, which disclosure is incorporated herein by reference. The referenced implementation concerns treatment of simian HIV-infected macaques with whole 1F7. A readily adaptable application to humans using peptide fragments of 1F7 is envisioned. Similarly, modulation of the immune response in humans infected with HIV is contemplated using one or more of an aforementioned polynucleotide, preferably a vector, encoding at least one peptide fragment of 1F7. Such a polynucleotide is conveniently administered directly to tissues, e.g., muscle tissue, of the host, either alone or in combination with a transfection-assisting agent such as a cationic lipid, liposome, or the like, as is well-known.

The present invention is further illustrated by the following example, which is offered to explain more particularly the invention, without in any way limiting it.

Example. Determination of the VH and VL Gene Sequences of Antibody 1F7

To isolate and determine the native nucleotide sequences of the hybridoma that encodes the VH and VL genes Mab 1F7, messenger RNA was isolated from 1×10^7 cells of the HB hybridoma. First strand cDNA were synthesized using the SuperScript Preamplification System (Gibco BRL; Gaithersburg, MD). The 1F7 heavy and light genes were amplified by PCR using the following primers:

1F7 heavy chain:

5' primer: 5'-actagtcgacatgaaatgcagctgggtcatsttcttc-3' (SEQ ID NO: 1)

3' primer: 5'-cccaagcttacgagggggaagacatttgggaa-3' (SEQ ID NO: 2)

1F7 light chain:

5' primer: 5'-gggaattcatggagacagacacactcctgctat-3' (SEQ ID NO: 3)

3' primer: 5'-cccaagcttactggatggtgggaagatgga-3' (SEQ ID NO: 4)

where s = c or g.

The amplified products were cloned in pT7 Blue T-vector (Novagen; Madison, WI). At least three clones were selected for sequencing with a T7 promoter primer and U-19mer primer using Sequenase Version 2.0 Kit (USB; Cleveland, OH).

The nucleotide sequences obtained for the VH and VL genes are shown in SEQ ID NOS: 5 and 22, respectively, and the corresponding translations are given in SEQ ID NOS: 6 and 23. The amino acid sequences of the VH and VL chains of the 1F7 antibody have been disclosed previously [Wang, Q., *et al.*, *J. Clin. Invest.* (1995), 96: 775-780], although this reference contains errors in its Fig. 1 involving mislabeled VH and VL chains and a switching of residues 61-70 between 1F7 and M-T310 in the VL chain. Also, see U.S. Patent No. 6,057,421. The nucleotide sequences have not been previously disclosed.

The present invention has been described with reference to particular examples and modifications thereof for purposes of clarity and understanding. It should be appreciated that further modifications and improvements are contemplated within the scope of the appended claims.

SEQUENCE LISTING

<110> Mueller, Sybille, Kohler, Heinz

<120> NUCLEOTIDE SEQUENCES ENCODING VARIABLE REGIONS OF HEAVY AND LIGHT CHAINS OF MONOCLONAL ANTIBODY 1F7, AN ANTI-IDIOTYPIC ANTIBODY REACTIVE WITH ANTI-HIV ANTIBODIES

<130> 200-013

<160> 38

<170> PatentIn version 3.0

<210> 1

<211> 37

<212> DNA

<213> mouse

<220>

<221> primer_bind

<222> (1)..(37)

<223> 1F7 heavy chain 5' primer

<400> 1

actagtcgac atgaaatgca gctgggtcat sttcttc

37

<210> 2

<211> 32

<212> DNA

<213> mouse

<220>

<221> primer_bind

<222> (1)..(32)

<223> 1F7 heavy chain 3' primer

<400> 2

cccaagctta cgagggggaa gacatttggg aa

32

<210> 3

<211> 33

<212> DNA

<213> mouse

<220>

<221> primer_bind

<222> (1)..(33)

<223> 1F7 light chain 5' primer

<400> 3

gggaattcat ggagacagac acactcctgc tat

33

<210> 4
 <211> 30
 <212> DNA
 <213> mouse

<220>
 <221> primer_bind
 <222> (1)..(30)
 <223> 1F7 light chain 3' primer

<400> 4
 cccaagctta ctggatggtg ggaagatgga 30

<210> 5
 <211> 363
 <212> DNA
 <213> mouse

<220>
 <221> gene
 <222> (1)..(362)
 <223> 1F7 VH chain gene

<400> 5
 caggttactc tgaaagagtc tggccctggg atattgcagc cctcccagac cctcagtctg 60
 acttgttctt tctctggggtt ttcactgagc acttctggta tgggtgtgag ctggattcga 120
 cagccttcag gaaaggggtct ggagtggctg gcacacattt actgggatga tgacaagcgc 180
 tataacccat ccctgaagag ccggcttaca atctccaagg atacctccag caaccaggta 240
 ttctctcaaga tcaccagtgt ggacactcga gatactgcca catactactg tgctcgaagg 300
 gtctctctaa ctgcctatgc tatggactac tgggggtcaag gaacctcagt caccgtctcc 360
 tca 363

<210> 6
 <211> 363
 <212> DNA
 <213> mouse

<220>
 <221> CDS
 <222> (1)..(363)
 <223> 1F7 VH chain gene

<400> 6
 cag gtt act ctg aaa gag tct ggc cct ggg ata ttg cag ccc tcc cag 48
 Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Pro Ser Gln
 1 5 10 15

acc ctc agt ctg act tgt tct ttc tct ggg ttt tca ctg agc act tct 96
 Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser
 20 25 30

ggg atg ggt gtg agc tgg att cga cag cct tca gga aag ggt ctg gag 144
 Gly Met Gly Val Ser Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu
 35 40 45

tgg ctg gca cac att tac tgg gat gat gac aag cgc tat aac cca tcc 192
 Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
 50 55 60

ctg aag agc cgg ctt aca atc tcc aag gat acc tcc agc aac cag gta 240
 Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Ser Asn Gln Val
 65 70 75 80

ttc ctc aag atc acc agt gtg gac act cga gat act gcc aca tac tac 288
 Phe Leu Lys Ile Thr Ser Val Asp Thr Arg Asp Thr Ala Thr Tyr Tyr
 85 90 95

tgt gct cga agg gtc tct cta act gcc tat gct atg gac tac tgg ggt 336
 Cys Ala Arg Arg Val Ser Leu Thr Ala Tyr Ala Met Asp Tyr Trp Gly
 100 105 110

caa gga acc tca gtc acc gtc tcc tca 363
 Gln Gly Thr Ser Val Thr Val Ser Ser
 115 120

<210> 7
 <211> 121
 <212> PRT
 <213> mouse

<400> 7
 Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Pro Ser Gln
 1 5 10 15

Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser
 20 25 30

Gly Met Gly Val Ser Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu
 35 40 45

Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
 50 55 60

Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Ser Asn Gln Val
 65 70 75 80

Phe Leu Lys Ile Thr Ser Val Asp Thr Arg Asp Thr Ala Thr Tyr Tyr
 85 90 95

CCP4 2.1.10

Cys Ala Arg Arg Val Ser Leu Thr Ala Tyr Ala Met Asp Tyr Trp Gly
 100 105 110

Gln Gly Thr Ser Val Thr Val Ser Ser
 115 120

<210> 8
 <211> 90
 <212> DNA
 <213> mouse

<220>
 <221> CDS
 <222> (1)..(90)
 <223> 1F7 VH FR1 sequence

<400> 8
 cag gtt act ctg aaa gag tct ggc cct ggg ata ttg cag ccc tcc cag 48
 Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Pro Ser Gln
 1 5 10 15
 acc ctc agt ctg act tgt tct ttc tct ggg ttt tca ctg agc 90
 Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser
 20 25 30

<210> 9
 <211> 30
 <212> PRT
 <213> mouse

<400> 9
 Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Pro Ser Gln
 1 5 10 15
 Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser
 20 25 30

<210> 10
 <211> 21
 <212> DNA
 <213> mouse

<220>
 <221> CDS
 <222> (1)..(21)
 <223> 1F7 VH CDR1 sequence

<400> 10
 act tct ggt atg ggt gtg agc 21
 Thr Ser Gly Met Gly Val Ser
 1 5

<210> 11
 <211> 7
 <212> PRT
 <213> mouse

<400> 11
 Thr Ser Gly Met Gly Val Ser
 1 5

<210> 12
 <211> 42
 <212> DNA
 <213> mouse

<220>
 <221> CDS
 <222> (1)..(42)
 <223> 1F7 VH FR2 sequence

<400> 12
 tgg att cga cag cct tca gga aag ggt ctg gag tgg ctg gca
 Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu Trp Leu Ala
 1 5 10

42

<210> 13
 <211> 14
 <212> PRT
 <213> mouse

<400> 13
 Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu Trp Leu Ala
 1 5 10

<210> 14
 <211> 48
 <212> DNA
 <213> mouse

<220>
 <221> CDS
 <222> (1)..(48)
 <223> 1F7 VH CDR2 sequence

<400> 14
 cac att tac tgg gat gat gac aag cgc tat aac cca tcc ctg aag agc
 His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser Leu Lys Ser
 1 5 10 15

48

<210> 15
 <211> 16
 <212> PRT
 <213> mouse

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

<400> 15
 His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser Leu Lys Ser
 1 5 10 15

<210> 16
 <211> 96
 <212> DNA
 <213> mouse

<220>
 <221> CDS
 <222> (1)..(96)
 <223> 1F7 VH FR3 sequence

<400> 16
 cgg ctt aca atc tcc aag gat acc tcc agc aac cag gta ttc ctc aag 48
 Arg Leu Thr Ile Ser Lys Asp Thr Ser Ser Asn Gln Val Phe Leu Lys
 1 5 10 15

atc acc agt gtg gac act cga gat act gcc aca tac tac tgt gct cga 96
 Ile Thr Ser Val Asp Thr Arg Asp Thr Ala Thr Tyr Tyr Cys Ala Arg
 20 25 30

<210> 17
 <211> 32
 <212> PRT
 <213> mouse

<400> 17
 Arg Leu Thr Ile Ser Lys Asp Thr Ser Ser Asn Gln Val Phe Leu Lys
 1 5 10 15

Ile Thr Ser Val Asp Thr Arg Asp Thr Ala Thr Tyr Tyr Cys Ala Arg
 20 25 30

<210> 18
 <211> 33
 <212> DNA
 <213> mouse

<220>
 <221> CDS
 <222> (1)..(33)
 <223> 1F7 VH CDR3 sequence

<400> 18
 agg gtc tct cta act gcc tat gct atg gac tac 33
 Arg Val Ser Leu Thr Ala Tyr Ala Met Asp Tyr
 1 5 10

<210> 19
 <211> 11
 <212> PRT
 <213> mouse

<400> 19
 Arg Val Ser Leu Thr Ala Tyr Ala Met Asp Tyr
 1 5 10

<210> 20
 <211> 33
 <212> DNA
 <213> mouse

<220>
 <221> CDS
 <222> (1)..(33)
 <223> 1F7 VH FR4 sequence

<400> 20
 tgg ggt caa gga acc tca gtc acc gtc tcc tca 33
 Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
 1 5 10

<210> 21
 <211> 11
 <212> PRT
 <213> mouse

<400> 21
 Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
 1 5 10

<210> 22
 <211> 330
 <212> DNA
 <213> mouse

<220>
 <221> gene
 <222> (1)..(330)
 <223> 1F7 VL chain gene

<400> 22
 gacattgtgc tcaccaattc tccagcttct ttggctgtgt ctctagggca gagggccacc 60
 atctcctgca aggccagcca aagtgttgat tatgatggtg atagttatat gtggtaccaa 120
 cagaaaccag gacagccacc caaactcctc acctatgctg catccaatct agaatctggg 180
 atcccagcca ggttttagtgg cagtgggtct gggacagact tcaccctcaa catccatcct 240
 gtggaggagg aggatgctgc aacctattac tgtcagcttt gtaatgagga tcctcccacg 300

ttcgggtgctg ggaccaagct ggagctgaaa

330

<210> 23
<211> 330
<212> DNA
<213> mouse

<220>
<221> CDS
<222> (1)..(330)
<223> 1F7 VL chain gene

<400> 23
gac att gtg ctc acc aat tct cca gct tct ttg gct gtg tct cta ggg 48
Asp Ile Val Leu Thr Asn Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
1 5 10 15

cag agg gcc acc atc tcc tgc aag gcc agc caa agt gtt gat tat gat 96
Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp
20 25 30

ggt gat agt tat atg tgg tac caa cag aaa cca gga cag cca ccc aaa 144
Gly Asp Ser Tyr Met Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys
35 40 45

ctc ctc acc tat gct gca tcc aat cta gaa tct ggg atc cca gcc agg 192
Leu Leu Thr Tyr Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg
50 55 60

ttt agt ggc agt ggg tct ggg aca gac ttc acc ctc aac atc cat cct 240
Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro
65 70 75 80

gtg gag gag gag gat gct gca acc tat tac tgt cag ctt tgt aat gag 288
Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Leu Cys Asn Glu
85 90 95

gat cct ccc acg ttc ggt gct ggg acc aag ctg gag ctg aaa 330
Asp Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
100 105 110

<210> 24
<211> 110
<212> PRT
<213> mouse

<400> 24
Asp Ile Val Leu Thr Asn Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
1 5 10 15

Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp
20 25 30

<220>
 <221> CDS
 <222> (1)..(42)
 <223> 1F7 VL CDR1 sequence

<400> 27
 aag gcc agc caa agt gtt gat tat gat ggt gat agt tat atg
 Lys Ala Ser Gln Ser Val Asp Tyr Asp Gly Asp Ser Tyr Met
 1 5 10

42

<210> 28
 <211> 14
 <212> PRT
 <213> mouse

<400> 28
 Lys Ala Ser Gln Ser Val Asp Tyr Asp Gly Asp Ser Tyr Met
 1 5 10

<210> 29
 <211> 45
 <212> DNA
 <213> mouse

<220>
 <221> CDS
 <222> (1)..(45)
 <223> 1F7 VL FR2 sequence

<400> 29
 tgg tac caa cag aaa cca gga cag cca ccc aaa ctc ctc acc tat
 Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Thr Tyr
 1 5 10 15

45

<210> 30
 <211> 15
 <212> PRT
 <213> mouse

<400> 30
 Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Thr Tyr
 1 5 10 15

<210> 31
 <211> 21
 <212> DNA
 <213> mouse

<220>
 <221> CDS
 <222> (1)..(21)
 <223> 1F7 VL CDR2 sequence

<400> 31
 gct gca tcc aat cta gaa tct
 Ala Ala Ser Asn Leu Glu Ser
 1 5

21

<210> 32
 <211> 7
 <212> PRT
 <213> mouse

<400> 32
 Ala Ala Ser Asn Leu Glu Ser
 1 5

<210> 33
 <211> 96
 <212> DNA
 <213> mouse

<220>
 <221> CDS
 <222> (1)..(96)
 <223> 1F7 VL FR3 sequence

<400> 33
 ggg atc cca gcc agg ttt agt ggc agt ggg tct ggg aca gac ttc acc 48
 Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
 1 5 10 15

ctc aac atc cat cct gtg gag gag gag gat gct gca acc tat tac tgt 96
 Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys
 20 25 30

<210> 34
 <211> 32
 <212> PRT
 <213> mouse

<400> 34
 Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
 1 5 10 15

Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys
 20 25 30

<210> 35
 <211> 27
 <212> DNA
 <213> mouse

```
<400> 38
Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
1          5          10
```